Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ADP-A2M4CD8 |
Synonyms | |
Therapy Description |
ADP-A2M4CD8 comprises autologous T-cells engineered to express a CD8alpha co-receptor and a T-cell receptor (TCR) targeting MAGE-A4, which potentially induces antitumor activity (J Clin Oncol 41, 2023 (suppl 6; abstr 517)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADP-A2M4CD8 | Uzatresgene autoleucel|MAGE-A4 SPEAR CD8alpha T-cells|uza-cel | ADP-A2M4CD8 comprises autologous T-cells engineered to express a CD8alpha co-receptor and a T-cell receptor (TCR) targeting MAGE-A4, which potentially induces antitumor activity (J Clin Oncol 41, 2023 (suppl 6; abstr 517)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05601752 | Phase II | ADP-A2M4CD8 | ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) | Recruiting | USA | GBR | FRA | ESP | CAN | 0 |